❌

Reading view

UnitBoost: Managing Compound LLM Systems with a Merge Operator, Not a Model

arXiv:2609.09815v1 Announce Type: new Abstract: Compound LLM systems often solve a coordination problem by adding a higher-level LLM. The resulting meta-agent reads workers' outputs, writes the final answer, allocates later calls, and decides when to stop. It is expressive, but it also concentrates three control decisions in an opaque, order-sensitive model call. We ask whether the manager needs to be generative at all. UnitBoost replaces that model with a defined meta-level operator: a task-given unit map turns worker outputs into slot-value proposals, a constrained argmax assembles the output, and the slots left unfilled or unsupported become an explicit residual for the next round. The operator is order-free, records unit provenance, and gives a simple guarantee: without coupling constraints, unit-wise maximization under the same admission score dominates selection of any complete candidate. On three held-out benchmarks, it exceeds the best single candidate chosen with gold labels by 0.060-0.195 absolute task-score points and input-matched generative managers by 0.048-0.076. Replacing only the management step improves six compound-system configurations by 0.013-0.182. Residual-directed rounds raise FanOutQA cell F1 from 0.4778 to 0.5524; matched controls show that the true residual outperforms random targets and ordinary rereading, while a label-free supply signal flags exhaustion after one unproductive round. The same analysis measures three conditions in which no such gain is available (one indivisible unit, unavailable unit identity, and an endpoint that charges for every emitted unit) and quantifies cross-unit coupling as a repair cost. The manager gives up semantic freedom and gains order invariance, unit provenance, and testable failure conditions.
  •  

Pulmonary nodule prediction in the multi-omics era: Integrating radiomics, AI, liquid biopsy, and airway classifiers

Crit Rev Oncol Hematol. 2026 Sep;225:105483. doi: 10.1016/j.critrevonc.2026.105483. Epub 2026 Jul 10.

ABSTRACT

Low-dose CT (LDCT) lung cancer screening significantly reduces mortality but has dramatically increased the detection of pulmonary nodules. Most of these nodules are benign, leading to a high false-positive rate that triggers unnecessary invasive procedures and patient anxiety, underscoring the need for more precise noninvasive diagnostic tools. Critically, single-modality liquid biopsy biomarkers, including circulating tumor cells, cell-free DNA mutations, or individual microRNAs, have demonstrated insufficient sensitivity or specificity for independent clinical deployment when used in isolation. This necessitates a paradigm shift toward multimodal molecular integration, wherein complementary biomarker classes are combined to overcome the inherent limitations of any single analyte. Traditional clinical prediction models (Mayo, VA, Brock, Herder) assist in estimating malignancy risk, yet their accuracy remains modest. Emerging approaches harness radiomics and artificial intelligence (AI) to extract high-dimensional imaging features from chest CT scans, improving risk stratification beyond human assessment alone. In parallel, minimally invasive liquid biopsy biomarkers offer complementary avenues to detect occult malignancy signals. Additionally, bronchial airway gene expression classifiers leverage the "field-of-injury" effect in normal respiratory epithelium to help identify lung cancer even when the nodule itself cannot be directly sampled via biopsy. Integrating these radiologic and molecular data streams into a multi-omics framework has the potential to enhance diagnostic precision for indeterminate pulmonary nodules, enabling more confident discrimination between benign and malignant lesions. However, most of these emerging tools have not yet been validated in large prospective trials and face technological barriers as well as challenges in real-world implementation. This review focuses primarily on LDCT screening detected pulmonary nodules, while incorporating evidence from incidentally detected and other indeterminate nodule cohorts when relevant to broader CT based management. By synthesizing advances in radiomics, AI, liquid biopsy, airway classifiers, and multi-omics integration, we highlight the need for prospective validation and multidisciplinary collaboration to translate these approaches into clinically useful pathways that improve early lung cancer detection, reduce unnecessary interventions, and enhance patient outcomes.

PMID:42431477 | DOI:10.1016/j.critrevonc.2026.105483

  •  
❌